Document is current
Any future updates will be listed below
-
Authors
Sangro, Bruno https://orcid.org/0000-0002-4177-6417
Sarobe, Pablo https://orcid.org/0000-0003-0503-7905
Hervás-Stubbs, Sandra https://orcid.org/0000-0003-3391-1516
Melero, Ignacio https://orcid.org/0000-0002-1360-348X
- License Information
-
More Information
Article History
Accepted: 5 March 2021
First Online: 13 April 2021
Competing interests
: I.M. reports advisory roles with Roche-Genentech, Bristol-Myers Squibb, CYTOMX, Incyte, MedImmune, Tusk, F-Star, Genmab, Molecular Partners, Alligator, Bioncotech, MSD, Merck Serono, Boehringer Ingelheim, Astra Zeneca, Numab, Catalym and Bayer, and research funding from Roche, BMS, Alligator and Bioncotech. B.S. reports consultancy fees from Adaptimmune, Astra Zeneca, Bayer, BMS, BTG, Eli Lilly, Ipsen, Novartis, Merck, Roche, Sirtex Medical and Terumo and speaker fees from Astra Zeneca, Bayer, BMS, BTG, Eli Lilly, Ipsen, Novartis, Merck, Roche, Sirtex Medical, Terumo BMS and Sirtex Medical. P.S. and S.H.-S. report no competing interests.
